Feed HRMY
HR

Harmony Biosciences Holdings, Inc.

HRMY · NASDAQ

$42.02 -1.29% (-$0.55)
1M +10.14%
Market Cap $2.47B
P/E Ratio 13.65x
Div. Yield -
ROE 20.06%

Bulios Fair Price

$55.29

31.6% upside

Current Price

$42.02

Undervalued Fair Value Overvalued

According to Bulios Fair Price, HRMY is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
5/9
Valuation
87 /100
Cheap
P/E 13.65x
EV/EBITDA 7.52x
P/S 2.58x
Growth
74 /100
Growing
EPS growth 3.01%
Rev. growth 25.64%
FCF growth 34.09%
Profitability
99 /100
Strong
Gross margin 75.42%
Net margin 18.88%
Op. margin 24.03%
Quality
83 /100
Excellent
ROIC 14.96%
ROE 20.06%
ROA 13.20%
Debt
100 /100
Low
Debt/Equity 0.15x
Current ratio 3.48x
Int. coverage 18.62x
Stability
90 /100
Stable
Beta 0.93x
Rev. volatility 6.25%
EPS volatility 24.29%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about HRMY
Online

About the company

Harmony Biosciences Holdings, Inc. (HRMY) is an American company specializing in research, development, and commercialization of drugs and therapies for sleep disorders and neurological conditions. With activities in biotechnology and pharmaceuticals, Harmony Biosciences Holdings is a key player in the world of sleep disorder and neurological condition treatment. Their research focuses on innovative treatment approaches and therapies for various sleep disorders, such as narcolepsy. The company aims to improve the lives of patients suffering from these conditions and provide modern treatment solutions. Harmony Biosciences Holdings is characterized by expertise in neurology and the treatment of sleep disorders. Harmony Biosciences Holdings, Inc. (HRMY) shares could be suitable for investors looking for an investment opportunity in the biotechnology and pharmaceutical sector with a company focused on innovations in the treatment of sleep disorders and neurological conditions and enhancing the quality of life for patients.

Sector

Healthcare

Industry

Biotechnology

CEO

Jeffrey Dayno

Employees

293

Headquarters

Plymouth Meeting

Upcoming events

03 NOV

Earnings

Upcoming earnings report

44d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.